{"filing":{"accession_number":"0001339970-26-000039","cik":"0001339970","ticker":"ATYR","company_name":"aTYR PHARMA INC","form":"8-K","filing_date":"2026-06-08","report_date":null,"primary_document":"atyr-20260603.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1339970/000133997026000039/atyr-20260603.htm"},"events":[{"id":6272,"run_id":5496,"accession_number":"0001339970-26-000039","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"aTyr Pharma received a deficiency notice on December 4, 2025, for failing to maintain a minimum closing bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). Although the company was granted a second 180-day compliance period (until November 30, 2026) on June 3, 2026, the filing explicitly states that failure to regain compliance by that date will result in a delisting notice, with only the possibility of appeal. This is a material delisting risk disclosure under Item 3.01.","company_name":"aTYR PHARMA INC","ticker":"ATYR","filing_date":"2026-06-08","submitted_at":null,"items":[{"id":5163,"accession_number":"0001339970-26-000039","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"aTyr Pharma received a deficiency notice on December 4, 2025, for failing to maintain a minimum closing bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). Although the company was granted a second 180-day compliance period (until November 30, 2026) on June 3, 2026, the filing explicitly states that failure to regain compliance by that date will result in a delisting notice, with only the possibility of appeal. This is a material delisting risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T20:06:17.270702+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5163,"accession_number":"0001339970-26-000039","item_number":"3.01","item_title":"Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"aTyr Pharma received a deficiency notice on December 4, 2025, for failing to maintain a minimum closing bid price of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). Although the company was granted a second 180-day compliance period (until November 30, 2026) on June 3, 2026, the filing explicitly states that failure to regain compliance by that date will result in a delisting notice, with only the possibility of appeal. This is a material delisting risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T20:06:17.270702+00:00","company_name":"aTYR PHARMA INC","ticker":"ATYR","filing_date":"2026-06-08"}]}